Report from the CVOT Summit 2020: new cardiovascular and renal outcomes

Cardiovascular Diabetology

Thomas Forst¹  Mikhail Kosiborod²  Hiddo J. L. Heersprink³  Francesco Giorgino⁴  Oliver Schnell⁵  Eberhard Standl⁵  Francesco Cosentino⁶  Xavier Cos⁷  Christoph Wanner⁸ 

[1] CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany;Cardiometabolic Center of Excellence, University of Missouri-Kansas City, Kansas, MO, USA;Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands;Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy;Forschergruppe Diabetes e. V., Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany;Karolinska University Hospital, Solna, Stockholm, Sweden;Sant Marti de Provençals Primary Care Centres, Barcelona, Spain;Universitätsklinikum Würzburg, Würzburg, Germany;

关键词: Diabetes;    Cardiovascular disease;    Heart failure;    Chronic kidney disease;    Obesity;    VERTIS-CV;    EMPEROR-Reduced;    DAPA-CKD;    FIDELIO-DKD;    SGLT2i inhibitor;    GLP-1 receptor agonist;    Mineralocorticoid receptor antagonist;   

DOI  :  10.1186/s12933-021-01254-1

来源: Springer

【 摘 要 】

The 6th Cardiovascular Outcome Trial (CVOT) Summit “Cardiovascular and Renal Outcomes 2020” was the first to be held virtually on October 29–30, 2020. As in previous years, this summit served as reference meeting for in-depth discussions on the topic of recently completed and presented major outcome trials. This year, focus was placed on the outcomes of VERTIS-CV, EMPEROR-Reduced, DAPA-CKD, and FIDELIO-DKD. Trial implications for diabetes management and the impact on new treatment algorithms were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists, and general practitioners. Discussion evolved from major outcome trials using SGLT-2 inhibitors for treatment and prevention of heart failure and chronic kidney disease in people with and without diabetes, to additional therapy options for chronic kidney disease with a novel mineralocorticoid receptor antagonist. Furthermore, challenges in diabetes management like COVID-19 and obesity, as well as novel treatment strategies and guidelines, were discussed.The 7th Cardiovascular Outcome Trial Summit will be held virtually on November, 18–19, 2021 (http://www.cvot.org).

【 授权许可】

CC BY